Comparative Pharmacology
Head-to-head clinical analysis: BICILLIN versus PENICILLIN 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BICILLIN versus PENICILLIN 2.
BICILLIN vs PENICILLIN-2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzathine penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and autolysin inhibition, leading to cell lysis.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Benzathine penicillin G 1.2 million units intramuscularly once for early syphilis; 2.4 million units intramuscularly weekly for 3 weeks for late latent syphilis.
250 mg orally every 6 hours or 500 mg orally every 8 hours for mild to moderate infections; intravenous dosing: 1-2 million units every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life: 0.5–1 hour (prolonged in renal impairment); clinical context: requires probenecid for extended action
30-60 minutes; prolonged in renal impairment (up to 10 hours in anuria)
Primarily renal (60–70% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%)
Renal: 60-80% unchanged; biliary/fecal: minor (10-20%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic